Welcome!

News Feed Item

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014" provides data on the Gastroesophageal (GE) Junction Carcinomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroesophageal (GE) Junction Carcinomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Introduction 7
Gastroesophageal (GE) Junction Carcinomas 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Gastroesophageal (GE) Junction Carcinomas 26
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Gastroesophageal (GE) Junction Carcinomas 35
May 16, 2012: Amgen Presents Results From Exploratory Biomarker Analysis Of Rilotumumab 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Amgen Inc. 38
Clinical Trial Overview of Amgen Inc. 38
Novartis AG 39
Clinical Trial Overview of Novartis AG 39
Bristol-Myers Squibb Company 40
Clinical Trial Overview of Bristol-Myers Squibb Company 40
Eli Lilly and Company 41
Clinical Trial Overview of Eli Lilly and Company 41
C. H. Boehringer Sohn AG & Co. KG 42
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 42
Dainippon Sumitomo Pharma Co., Ltd. 43
Clinical Trial Overview of Dainippon Sumitomo Pharma Co., Ltd. 43
Aphton Corporation (Inactive) 44
Clinical Trial Overview of Aphton Corporation (Inactive) 44
Amgen research GmbH 45
Clinical Trial Overview of Amgen research GmbH 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
North Central Cancer Treatment Group 48
Clinical Trial Overview of North Central Cancer Treatment Group 48
Case Comprehensive Cancer Center 49
Clinical Trial Overview of Case Comprehensive Cancer Center 49
Stanford University 50
Clinical Trial Overview of Stanford University 50
Sidney Kimmel Comprehensive Cancer Center 51
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 51
Memorial Sloan Kettering Cancer Center 52
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 52
Southwest Oncology Group 53
Clinical Trial Overview of Southwest Oncology Group 53
University of Pittsburgh 54
Clinical Trial Overview of University of Pittsburgh 54
Fox Chase Cancer Center 55
Clinical Trial Overview of Fox Chase Cancer Center 55
The University of Texas M. D. Anderson Cancer Center 56
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 107

List of Tables

Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region, 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 38
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 39
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 40
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 41
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 42
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Dainippon Sumitomo Pharma Co., Ltd., 2014* 43
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Aphton Corporation (Inactive), 2014* 44
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen research GmbH, 2014* 45
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 48
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 49
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 50
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 51
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 52
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 53
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 54
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014* 55
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 56

List of Figures
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 105

To order this report: Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
Given the popularity of the containers, further investment in the telco/cable industry is needed to transition existing VM-based solutions to containerized cloud native deployments. The networking architecture of the solution isolates the network traffic into different network planes (e.g., management, control, and media). This naturally makes support for multiple interfaces in container orchestration engines an indispensable requirement.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...